This Medudy course is a video tutorial for physicians on the topic of "Ziresovir in infants with RSV infection". The format used here is a so-called "Journal Club Summary", in which we summarize the latest and most clinically relevant studies for you.
Respiratory syncytial virus (RSV) is one of the main causes of severe illness in infants. However, there is currently no highly effective therapy. Ziresovir is an orally administered antiviral agent that inhibits the RSV fusion protein F and has already shown an antiviral effect. To evaluate its efficacy and safety, today's phase 3 AIRFLO study was conducted in hospitalized children with RSV infection.
Note: All "speakers" appearing in the Medudy videos are AI-based avatars used to improve the didactics of the videos. The people on whom the avatars are based have explicitly consented to their use. All content is based on high-quality scientific sources and is created and reviewed by the Medudy medical team.
This "Journal Club Summary" in video format focuses on ziresovir - an orally administered drug for the treatment of RSV in infants - and its potential importance for optimizing the treatment of this common respiratory disease.
At the end of this training you will know:
- the clinical background and relevance of the research question under investigation
- Study design and methodology of the publication to answer the research question
- the results and key takeaways of the publication
- the conclusion of the publication and possible limitations
